Moderna Hits a Short-Term Vaccine Manufacturing Delay, Still on Track for First 100 Million Doses by End of March

Moderna (NASDAQ:MRNA) has hit a bit of a snag with the manufacturing of its COVID-19 vaccine. The company's fill-and-finish contractor, Catalent (NYSE:CTLT), is experiencing delays with some of the doses it's responsible for getting out the door. The companies didn't disclose exactly what was causing the delay.